Drug Profile
Aticaprant - Eli Lilly and Company/Johnson & Johnson Innovative Medicine
Alternative Names: AVTX-501; CERC 501; JNJ-3964; JNJ-67953964; JNJ-67953964-AAA; LY 2456302Latest Information Update: 10 Oct 2023
Price :
$50
*
At a glance
- Originator Eli Lilly and Company
- Developer Johnson & Johnson Innovative Medicine; Rockefeller University
- Class Antidepressants; Benzamides; Drug withdrawal therapies; Pyrrolidines
- Mechanism of Action Opioid kappa receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase III Major depressive disorder
- Discontinued Alcoholism; Cocaine-related disorders; Smoking withdrawal
Most Recent Events
- 01 Oct 2023 Janssen Pharmaceuticals is now called Johnson & Johnson Innovative Medicine (Janssen Pharmaceuticals website, October 2023)
- 19 May 2023 Chemical structure information added
- 06 Dec 2022 Janssen Pharmaceuticals initiates a phase-III trial for Major depressive disorder (Adjunctive treatment) in USA (PO, Tablet) (NCT05550532) (EudraCT2022-000461-41)